Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sodium phosphate, dibasic + sodium phosphate, monobasic** is a combination oral or injectable drug comprised of sodium phosphate dibasic (disodium phosphate) and sodium phosphate monobasic (monosodium phosphate). It acts as an **osmotic laxative** by increasing fluid retention in the intestinal lumen, resulting in loose stools and subsequent bowel evacuation. The combination is primarily indicated for colon cleansing prior to colonoscopy in adults, and for the treatment or prevention of hypophosphatemia in patients who cannot receive oral phosphate supplements. As a phosphate replacement, it serves to restore low blood phosphorus. The mechanism involves drawing water into the intestines via osmotic effects of sodium ions, triggering diarrhea and effective bowel cleansing. It may also be administered intravenously as a phosphate additive in fluid preparations for patients with restricted oral intake[2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium phosphate, dibasic + sodium phosphate, monobasic.